Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies.

agreement framework health technology assessment (HTA) improvement of effective clinical benefit innovation payer reimbursement therapeutic added value

Journal

Frontiers in medical technology
ISSN: 2673-3129
Titre abrégé: Front Med Technol
Pays: Switzerland
ID NLM: 101772626

Informations de publication

Date de publication:
2022
Historique:
received: 10 04 2022
accepted: 12 08 2022
entrez: 22 9 2022
pubmed: 23 9 2022
medline: 23 9 2022
Statut: epublish

Résumé

The evaluation of pharmaceutical innovation and therapeutic value is an increasingly complex exercise for which different approaches are adopted at the national level, despite the need for standardisation of processes and harmonisation of public health decisions. The objective of our analysis was to compare the approaches of the AIFA (

Identifiants

pubmed: 36134249
doi: 10.3389/fmedt.2022.917151
pmc: PMC9483157
doi:

Types de publication

Journal Article

Langues

eng

Pagination

917151

Informations de copyright

© 2022 Xoxi, Di Bidino, Leone, Aiello and Prada.

Déclaration de conflit d'intérêts

Authors AA and MP are employed by Intexo SB. SL at the time of submission was employed by Intexo, now at The Janssen Pharmaceutical Companies. EX collaborates with Intexo as Senior Scientific Advisor. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Biochem Med (Zagreb). 2012;22(3):276-82
pubmed: 23092060
BMC Med Res Methodol. 2013 Jul 29;13:97
pubmed: 23890315
Front Med (Lausanne). 2021 Dec 08;8:793640
pubmed: 34957163
Health Econ Policy Law. 2020 Jul;15(3):386-402
pubmed: 31488229
Eur J Health Econ. 2018 Jan;19(1):123-152
pubmed: 28303438
Expert Rev Pharmacoecon Outcomes Res. 2020 Aug;20(4):405-409
pubmed: 31240965
Int J Technol Assess Health Care. 2021 Jul 15;37(1):e74
pubmed: 34261561
Front Pharmacol. 2017 Jun 30;8:384
pubmed: 28713265
BMJ Open. 2021 Jan 13;11(1):e041259
pubmed: 33441356
Stroke. 2015 Aug;46(8):e184-7
pubmed: 26106115
Int J Technol Assess Health Care. 2020 Jun;36(3):232-238
pubmed: 32538341
Clin Pharmacol Ther. 2020 Aug;108(2):350-357
pubmed: 32236959
BMJ. 2004 Jun 19;328(7454):1490
pubmed: 15205295
Br J Clin Pharmacol. 2020 Jan;86(1):93-105
pubmed: 31656055
Eur J Cancer. 2021 Mar;145:11-18
pubmed: 33412466
Front Pharmacol. 2021 Aug 10;12:699466
pubmed: 34456724

Auteurs

Entela Xoxi (E)

Intexo SB Rome Italy.
Postgraduate School of Health Economics and Management (ALTEMS), Università Cattolica del Sacro Cuore, Rome, Italy.

Rossella Di Bidino (R)

Health Technology Assessment Unit, Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Serena Leone (S)

Patient Access Unit, Intexo SB Milan Italy.

Andrea Aiello (A)

Patient Access Unit, Intexo SB Milan Italy.

Mariangela Prada (M)

Patient Access Unit, Intexo SB Milan Italy.

Classifications MeSH